Xinnovi completed a RMB 1 billion C round of financing, jointly led by Zhengxin Valley and internationally renowned long-term funds.

Guide: Xinnovi to raise 1 billion people's lives, is committed to new drug research and development on the market.
2020, Suzhou Xinnovi Pharmaceutical Technology Co., Ltd. ("Xinnovi") successfully completed a RMB 1 billion round of C financing.
The current round of financing by Zhengsin Valley Innovation Capital and the international well-known long-term fund joint venture, Haisong Capital, CHINA Capital's ZHONGKIN Kaide Fund, Core Cloud Capital, Kuyou Capital, Deguan Capital and other well-known institutions to participate in the current round of financing with the company as the exclusive financial adviser.
founded in 2016, Isinovy is an innovative pharmaceutical company focused on significantly unsolved clinical needs and with global intellectual property rights.
Xinnovi based on Suzhou headquarters, set up four branches in Beijing, Shanghai, Australia, Boston, built a complete global research and development and production system, the team includes the industry's top scientific research, clinical, production and sales personnel, has won many Suzhou unicorn breeding enterprises, Jiangsu Province, double creation plan, Gusu leading talent and other important awards.
company around the mature target of the new generation of Bestinclass products and new target Firstinclass products two strategic dimensions of a series of layout, there are currently 4 products into the domestic and foreign clinical stage, and another 4 products in the INDenabling stage, covering tumors, anti-infection, metabolism, autoimmune and other major areas.
this round of fund-raising will be mainly used to promote the company's ongoing domestic and foreign clinical trials, early project preclinical research and development and the construction of production bases, to promote the early launch of products to benefit the vast number of patients.
has entered the clinical product pipeline, XNW4107 is a new type of beta-endamidease inhibitor, has a strong lethality to Gloranian-negative bacteria, and works at the same time against Baumann bacteria, copper-green prosthetic monocytobacteria, E. coli bacteria, antibacterial effect is better than the existing market or clinical stage of similar products.
XNW3009 is a new generation of uric acid-lowering drugs, and current clinical data show good safety and excellent ability.
XNW1011 is the world's second co-price reversible mechanism of BTK inhibitors, and is expected to surpass the next generation in terms of safety, efficacy and adaptiveness.
XNW7201 is a small molecular inhibitor of the Wnt pathway, which is expected to show remarkable efficacy in the treatment of gastrointestinal tumors such as stomach cancer, colorectal cancer and pancreatic cancer, and can improve the immune response and be suitable for use in association with tumor immunosuppressants.
, founder and chairman of the Company, thanked well-known institutional investors and the Suzhou Park government for their support.
Xinnovi has built a sound team system, covering biology, pharmaceutical chemistry, CMC, translational medicine, clinical pharmacology, clinical, sales, capital markets and other links, and in each link is equipped with the industry's top professionals.
In the layout of the product line, but also fully consider the unseeded clinical needs and other similar products of differentiation advantages, taking into account the success rate of research and development and the commercial value of the product, the future Ofovi will keep its promise to maintain the initial heart, continue to focus on cancer, anti-infection and other major areas, and constantly enrich the product line, and strive to provide patients with more good medicine.
, as the lead investor in this round, said Mr. Lin Lijun, founder of Zhengxin Valley Innovation Capital: We are very honored to continue to support Xinnovi this round.
is focused on investing in great businesses, making the world a better place, supporting entrepreneurs who strive for excellence, and building world-class excellence through long-term, continuous efforts.
Xinnovi is an innovative pharmaceutical research and development company with strong independent research and development capabilities and systemic operation capabilities, the company is committed to developing a new generation of small molecule drugs for patients around the world, to solve the urgent clinical needs of anti-infection, tumors and so on, we are very optimistic about the company XNW41 07 and its successor products will continue to bring value to patients and society, in line with the "long-term, dedicated, al-Alistric" investment philosophy of Zhengxin Valley, Zhengxin Valley will also be a long-term firm support for Xinnovi's research and development, production, industrialization and sales, support Xinnovi to become the world's leading innovative drug research and development enterprises.
, managing director, said: Xinnovi is a rare domestic product with deep innovation and strong execution of the new drug head enterprises.
its unique pipeline positioning, but also in the domestic innovative pharmaceutical enterprises unique.
since its inception, Xinnovi along with the government, industry and capital of high recognition, in the company's headquarters in Suzhou City, Xinnovi has won many years of awards Grand Slam.
is honored to work with the team to provide financial advisory services for a star company such as Xinnovi, and sincerely wishes Xinnovi a successful landing in the capital market in the near future, growing into a China and the world's BigPharma! Founded in 2016, Xinnovi Suzhou Xinnovi Pharmaceutical Technology Co., Ltd. is an innovative pharmaceutical company focused on significantly unsolved clinical needs and with global intellectual property rights.
Xinnovi around the mature target Bestinclass products and the new target Firstinclass products two strategic dimensions of a series of layout, there are currently 4 products into the domestic and foreign clinical stage, and another 4 products in the INDenabling stage, covering tumors, anti-infection, metabolism, autoimmune and other major areas.
.